Guardant Health, Inc., a leading precision oncology company, has announced the pricing of its offering of US$1 billion aggregate principal amount of 0% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The issuance and sale of the notes are scheduled to settle on November 19, 2020, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional US$150 million principal amount of notes.
Latham & Watkins LLP represented Guardant in the offering with a corporate deal team led by Orange County partners Shayne Kennedy and Drew Capurro, with Orange County associates Benjamin Sosin, Nathan Wages, and Abby Timmons. Advice was also provided on convertible debt matters by New York partner Greg Rodgers, with Los Angeles counsel Arash Aminian Baghai and New York associate Ryan Gold; on equity derivatives matters by New York partner Catherine Lee, with New York associates Jack Neff and Ariel Robbins-Rothman; and on tax matters by New York partners Bora Bozkurt and Elena Romanova, with New York associates Ron Moore and Ted Gkoo.
